ATE502298T1 - Verfahren und materialien zur beurteilung von prostatakrebstherapien - Google Patents
Verfahren und materialien zur beurteilung von prostatakrebstherapienInfo
- Publication number
- ATE502298T1 ATE502298T1 AT04814409T AT04814409T ATE502298T1 AT E502298 T1 ATE502298 T1 AT E502298T1 AT 04814409 T AT04814409 T AT 04814409T AT 04814409 T AT04814409 T AT 04814409T AT E502298 T1 ATE502298 T1 AT E502298T1
- Authority
- AT
- Austria
- Prior art keywords
- prostate cancer
- androgens
- materials
- methods
- cancer therapies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53109103P | 2003-12-19 | 2003-12-19 | |
PCT/US2004/042221 WO2005060661A2 (en) | 2003-12-19 | 2004-12-16 | Methods and materials for assessing prostate cancer therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE502298T1 true ATE502298T1 (de) | 2011-04-15 |
Family
ID=34710203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04814409T ATE502298T1 (de) | 2003-12-19 | 2004-12-16 | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
Country Status (9)
Country | Link |
---|---|
US (1) | US8034548B2 (de) |
EP (2) | EP2299266A1 (de) |
JP (1) | JP2007514442A (de) |
AT (1) | ATE502298T1 (de) |
AU (1) | AU2004305075A1 (de) |
CA (1) | CA2550447A1 (de) |
DE (1) | DE602004031881D1 (de) |
NZ (1) | NZ548209A (de) |
WO (1) | WO2005060661A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
CN105902559A (zh) | 2005-08-01 | 2016-08-31 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
EP1937280B1 (de) | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Zusammensetzungen zur Therapie von Bcl2-assoziierten Tumoren |
ES2553442T3 (es) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
EP1968622B1 (de) | 2006-01-05 | 2014-08-27 | The Ohio State University Research Foundation | Mikro-rna-expressions-anomalien in pankreas- und azinus-tumoren |
EP2487258B1 (de) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | Verfahren auf Mikro-RNA-Basis zur Diagnose von Darmkrebs, Bauchspeicheldrüsenkrebs und Magenkrebs |
JP5523825B2 (ja) | 2006-03-20 | 2014-06-18 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ヒト巨核球形成間のマイクロrnaフィンガープリント |
PL2004181T6 (pl) | 2006-03-27 | 2023-09-04 | The Regents Of The University Of California | Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi |
CA2648139A1 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders |
EP2436785B1 (de) | 2006-07-13 | 2013-09-11 | The Ohio State University Research Foundation | Micro-ARN-29a zur Diagnose von Darm Adenokarzinom mit schlechter Uberlebensprognose. |
CA2663027A1 (en) | 2006-09-19 | 2008-08-14 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロrna発現サイン |
EP2109687B1 (de) | 2007-01-31 | 2014-06-04 | The Ohio State University Research Foundation | Micro-rna-basierte verfahren zur behandlung von akuter myeloischer leukämie (aml) |
WO2008112283A2 (en) * | 2007-03-12 | 2008-09-18 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment |
US8465917B2 (en) | 2007-06-08 | 2013-06-18 | The Ohio State University Research Foundation | Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells |
WO2008157319A1 (en) | 2007-06-15 | 2008-12-24 | The Ohio State University Research Foundation | ONCOGENIC ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING |
JP2010535782A (ja) | 2007-07-31 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | Dnmt3a及びdnmt3bを標的にすることによるメチル化を元に戻す方法 |
US8465918B2 (en) | 2007-08-03 | 2013-06-18 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
JP5770472B2 (ja) | 2007-08-22 | 2015-08-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | ヒト急性白血病におけるepha7及びerkリン酸化の調節解除を誘発するための方法及び組成物 |
UY31432A1 (es) | 2007-10-26 | 2009-05-29 | Compuestos de diarilhidantoina | |
CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
ES2600165T3 (es) * | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
ES2433940T3 (es) | 2008-06-11 | 2013-12-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia |
EP2504452A4 (de) | 2009-11-23 | 2014-06-11 | Univ Ohio State Res Found | Materialien und verfahren zur beeinflussung des wachstums, der migration und der invasion von tumorzellen |
US9108944B2 (en) | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
CN103648505B (zh) | 2010-11-12 | 2016-09-28 | 俄亥俄州立大学研究基金会 | 与微rna-21、错配修复和结肠直肠癌相关的材料和方法 |
EP2646553A4 (de) | 2010-11-12 | 2015-01-07 | Santaris Pharma As | Zusammensetzungen und verfahren zur behandlung androgenrezeptorabhängiger erkrankungen einschliesslich krebs |
WO2012068147A1 (en) | 2010-11-15 | 2012-05-24 | The Ohio State University Research Foundation | Controlled release mucoadhesive systems |
JP2014509852A (ja) | 2011-03-07 | 2014-04-24 | ジ・オハイオ・ステート・ユニバーシティ | マイクロRNA−155(miR−155)により誘導される変異誘発活性は炎症および癌を結び付ける |
AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
CN104685065B (zh) | 2012-01-20 | 2017-02-22 | 俄亥俄州立大学 | 浸润性和预后的乳腺癌生物标志物标签 |
EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
EP2912194B1 (de) | 2012-10-26 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | Androgenrezeptorvarianten und verfahren zur herstellung und verwendung |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
KR102417496B1 (ko) | 2019-11-29 | 2022-07-06 | (주)수파드엘릭사 | 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1472467A (en) | 1974-04-19 | 1977-05-04 | Wyeth John & Brother Ltd | Thiohydantoins |
FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
IL55774A (en) | 1977-10-28 | 1982-04-30 | Sparamedica Ag | Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture |
MC1220A1 (fr) | 1977-10-28 | 1979-07-20 | Hoffmann La Roche | Nouveaux derives d'imidazolidine |
ZA786739B (en) | 1977-12-01 | 1980-07-30 | Wellcome Found | Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations |
EP0004723A1 (de) | 1978-03-30 | 1979-10-17 | Beecham Group Plc | Deoxyhydantoine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
FR2449448B1 (fr) | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation |
FI801184A (fi) | 1979-04-24 | 1980-10-25 | Hoffmann La Roche | Foerfarande foer framstaellning av imidazolidinderivat |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
FR2619381B1 (fr) | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
US5614620A (en) | 1988-03-30 | 1997-03-25 | Arch Development Corporation | DNA binding proteins including androgen receptor |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
FR2656302B1 (fr) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveau procede de preparation de l'anandron et derives de l'anandron. |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2715402B1 (fr) | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
EP0721944B1 (de) | 1994-07-29 | 2001-01-17 | Suntory Limited | Imidazolidin-derivate und ihre verwendung |
FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
FR2741346B1 (fr) | 1995-11-16 | 1997-12-19 | Roussel Uclaf | Nouveau procede de preparation de derives phenylimidazolidine |
FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
WO1997019931A1 (en) | 1995-11-28 | 1997-06-05 | American Home Products Corporation | 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives |
FR2742749B1 (fr) | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
US6489163B1 (en) * | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
US5726061A (en) | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
US7053263B2 (en) | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
US6506607B1 (en) | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
BR9914018A (pt) | 1998-09-22 | 2001-07-03 | Yamanouchi Pharmaceuticals Co | Derivado de cianofenila |
US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
US6479063B2 (en) | 1999-12-27 | 2002-11-12 | Kenneth Weisman | Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis |
WO2002053155A1 (en) | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
HUP0402338A3 (en) | 2001-10-01 | 2008-10-28 | Bristol Myers Squibb Co | Spiro-hydantoin compounds, their use as anti-inflammatory agents, pharmaceutical compositions containing them and intermediates for preparing them |
US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
DE10218963A1 (de) | 2002-04-27 | 2003-11-20 | Aventis Pharma Gmbh | Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen |
TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
AU2003262717A1 (en) | 2002-08-15 | 2004-03-03 | Genzyme Corporation | Brain endothelial cell expression patterns |
FR2845384B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
JP2006510600A (ja) | 2002-10-04 | 2006-03-30 | ラボラトワール フルニエ エス・アー | 2−チオヒダントインに由来する化合物及び治療におけるその使用 |
FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
EP1634874A4 (de) | 2003-06-12 | 2008-04-02 | Chugai Pharmaceutical Co Ltd | Imidazolidinderivate |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
EP1709152A4 (de) * | 2003-12-15 | 2007-11-07 | Univ California | Molekulare signatur des pten-tumorsuppressors |
NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
CN1960725A (zh) | 2004-03-15 | 2007-05-09 | Ptc医疗公司 | 用于抑制血管发生的四环咔啉衍生物 |
EP1621539A1 (de) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocyclische-substituirte cyclische Harnstoffderivate, Verfaren zu ihrer Herstellung, und ihre pharmaceutische Verwendung als Kinase Inhibitoren |
JP4912148B2 (ja) | 2004-08-03 | 2012-04-11 | 中外製薬株式会社 | 新規イミダゾリジン誘導体 |
AU2005280908A1 (en) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
NZ591119A (en) | 2005-05-13 | 2012-08-31 | Univ California | Use of diarylhydantoin compounds for treating specific cancers |
PL2004181T6 (pl) | 2006-03-27 | 2023-09-04 | The Regents Of The University Of California | Modulator receptorów androgenowych do leczenia raka prostaty i chorób powiązanych z receptorami androgenowymi |
CA2648139A1 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders |
WO2008119015A2 (en) | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
-
2004
- 2004-12-16 AT AT04814409T patent/ATE502298T1/de not_active IP Right Cessation
- 2004-12-16 EP EP10011639A patent/EP2299266A1/de not_active Withdrawn
- 2004-12-16 EP EP04814409A patent/EP1709193B1/de not_active Not-in-force
- 2004-12-16 US US10/583,280 patent/US8034548B2/en active Active
- 2004-12-16 AU AU2004305075A patent/AU2004305075A1/en not_active Abandoned
- 2004-12-16 JP JP2006545417A patent/JP2007514442A/ja active Pending
- 2004-12-16 DE DE602004031881T patent/DE602004031881D1/de active Active
- 2004-12-16 NZ NZ548209A patent/NZ548209A/xx unknown
- 2004-12-16 WO PCT/US2004/042221 patent/WO2005060661A2/en active Application Filing
- 2004-12-16 CA CA002550447A patent/CA2550447A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1709193B1 (de) | 2011-03-16 |
EP1709193A2 (de) | 2006-10-11 |
WO2005060661A3 (en) | 2005-08-04 |
WO2005060661A2 (en) | 2005-07-07 |
NZ548209A (en) | 2009-07-31 |
AU2004305075A1 (en) | 2005-07-07 |
DE602004031881D1 (de) | 2011-04-28 |
CA2550447A1 (en) | 2005-07-07 |
EP1709193A4 (de) | 2007-11-14 |
JP2007514442A (ja) | 2007-06-07 |
EP2299266A1 (de) | 2011-03-23 |
US8034548B2 (en) | 2011-10-11 |
US20070166717A1 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE502298T1 (de) | Verfahren und materialien zur beurteilung von prostatakrebstherapien | |
CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
ATE408032T1 (de) | Esr1 und gebärmutterhalskrebs | |
DE602006016567D1 (de) | Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs | |
TW200622265A (en) | A method of designing a probe card apparatus with desired compliance characteristics | |
GB2477705A (en) | Methods and compositions of molecular profiling for disease diagnostics | |
CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
DE112005000151A5 (de) | Verwendung von Kern-Mantel-Partikeln | |
ATE550354T1 (de) | Humane ringspezifische bnp-antikörper | |
JP2010500565A5 (de) | ||
DE602006018143D1 (de) | (6-FLU0R-BENZ0Äl, 3ÜDIOXOLYL)-MORPHOLIN-4-YL-METHANONE UND DEREN VERWENDUNG ALS CBl-LIGANDEN | |
DE602004027992D1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
DE602004025463D1 (de) | Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol | |
ATE534905T1 (de) | Cop1-moleküle und verwendungen davon | |
GB2442365A (en) | Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders | |
Park et al. | Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+ 4 prostate cancers at biopsy: finding a new group eligible for active surveillance | |
ATE447628T1 (de) | Einzelsequenzhybridisierungssonden | |
ATE394676T1 (de) | Verbindungen und verfahren zur diagnose von prostatakrebs | |
ATE408712T1 (de) | Verfahren zur bestimmung des wiederauftretens von prostata krebs | |
WO2005094159A3 (en) | Methods of identifying neoplasm-specific antibodies and uses thereof | |
ATE491948T1 (de) | Gpr30-östrogenrezeptor bei mammakarzinomen | |
WO2006044439A3 (en) | Methods of identifying metastatic potential in cancer | |
Sinha et al. | Activated Chronic Lymphocytic Leukemia B-Cells Preferentially Shed CD52+ Microvesicles, but Not CD19+, and May Predict Therapeutic Outcome | |
Zhang et al. | Hydrologic Analysis for Kankakee River Watershed Streamflow Accounting Model | |
Jovane et al. | Integrated magnetobiostratigraphy, paleoclimatic and paleoceanographic inferences of the middle Eocene-Oligocene interval from the Monte Cagnero Section, central Italy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |